VIP and Growth Factors in the Infected Cornea

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2011 Jun 14

PMID 21666233

Citations 24

Authors

Xiaoyu Jiang

Sharon A McClellan

Ronald P Barrett

Elizabeth A Berger

Yunfan Zhang

Linda D Hazlett

Affiliations

Soon will be listed here.

Abstract

Purpose: Vasoactive intestinal peptide (VIP) is an anti-inflammatory neuropeptide that downregulates proinflammatory cytokines and promotes healing in a susceptible model of P. aeruginosa keratitis. Growth factors also play a role in corneal healing and restoration of tissue homeostasis after wounding. However, whether VIP treatment modulates growth factors to promote healing in the infected cornea remains untested and is the purpose of this study.

Methods: C57BL/6 (B6) mice were injected with VIP and mRNA and protein levels, and immunostaining for EGF, FGF, HGF, and VEGF-A were done. Exogenous treatment with a mixture of the growth factors also was tested and levels of cytokines, defensins, and bacterial counts were determined.

Results: Real-time RT-PCR, immunostaining, and ELISA data demonstrated that treatment with VIP enhanced levels of EGF, FGF, and HGF during disease, and that VEGF-A, and associated angiogenic molecules also were increased by VIP. Moreover, immunohistochemical studies confirmed that both epithelial and stromal cells participated in growth factor production. Most notably, treatment with a mixture of EGF, FGF, and HGF after disease onset, prevented corneal perforation when compared with controls. This outcome was associated with downregulation of proinflammatory cytokines such as macrophage inflammatory protein-2 (MIP-2), upregulation of anti-inflammatory cytokines such as TGF-β, and antimicrobials β-defensins 2 and 3, as well as decreased plate counts at 1 day postinfection (p.i.) (P = 0.0001).

Conclusions: Collectively, the data provide evidence that VIP treatment modulates growth factors, angiogenic molecules, and defensins in the infected cornea and that this in turn promotes healing and restoration of tissue homeostasis.

Citing Articles

PM dysregulates epithelial barrier function in human corneal epithelial cells that is restored by antioxidant SKQ1.

Somayajulu M, Wright R, Muhammed F, McClellan S, Ibrahim A, Hazlett L Toxicol Appl Pharmacol. 2024; 492:117122.

PMID: 39393465 PMC: 11563859. DOI: 10.1016/j.taap.2024.117122.

Modulating Growth Factor Receptor Signaling to Promote Corneal Epithelial Homeostasis.

Tarvestad-Laise K, Ceresa B Cells. 2023; 12(23).

PMID: 38067157 PMC: 10706396. DOI: 10.3390/cells12232730.

Retinal VIP-amacrine cells: their development, structure, and function.

Zhang X, Wang X, Zhu J, Chen K, Ullah R, Tong J Eye (Lond). 2023; 38(6):1065-1076.

PMID: 38066110 PMC: 11009269. DOI: 10.1038/s41433-023-02844-x.

A Novel Combination Therapy Tβ4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells.

Ebrahim A, Carion T, Ebrahim T, Win J, Kani H, Wang Y Biosensors (Basel). 2023; 13(11).

PMID: 37998149 PMC: 10669755. DOI: 10.3390/bios13110974.

Immunological consequences of compromised ocular immune privilege accelerate retinal degeneration in retinitis pigmentosa.

Mohan K, Mishra A, Muniyasamy A, Sinha P, Sahu P, Kesarwani A Orphanet J Rare Dis. 2022; 17(1):378.

PMID: 36253797 PMC: 9575261. DOI: 10.1186/s13023-022-02528-x.

References

Valdehita A, Carmena M, Collado B, Prieto J, Bajo A . Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul Pept. 2007; 144(1-3):101-8. DOI: 10.1016/j.regpep.2007.06.006. View

Szliter E, Lighvani S, Barrett R, Hazlett L . Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation. J Immunol. 2007; 178(2):1105-14. DOI: 10.4049/jimmunol.178.2.1105. View

Weigent D, Blalock J . Interactions between the neuroendocrine and immune systems: common hormones and receptors. Immunol Rev. 1987; 100:79-108. DOI: 10.1111/j.1600-065x.1987.tb00528.x. View

Nicosia R . What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?. Am J Pathol. 1998; 153(1):11-6. PMC: 1852942. DOI: 10.1016/S0002-9440(10)65539-3. View

Wayne Streilein J . Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003; 3(11):879-89. DOI: 10.1038/nri1224. View

Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S . Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006; 103(30):11405-10. PMC: 1544098. DOI: 10.1073/pnas.0506112103. View

Forster C, Cursiefen C, Kruse F . [Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment]. Ophthalmologe. 2008; 105(3):269-73. DOI: 10.1007/s00347-007-1527-8. View

Buret A, Olson M, Gall D, Hardin J . Effects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits. Infect Immun. 1998; 66(10):4917-23. PMC: 108608. DOI: 10.1128/IAI.66.10.4917-4923.1998. View

Iglewski B, Burns R, Gipson I . Pathogenesis of corneal damage from pseudomonas exotoxin A. Invest Ophthalmol Vis Sci. 1977; 16(1):73-6. View

10.

Kernacki K, Barrett R, Hobden J, Hazlett L . Macrophage inflammatory protein-2 is a mediator of polymorphonuclear neutrophil influx in ocular bacterial infection. J Immunol. 2000; 164(2):1037-45. DOI: 10.4049/jimmunol.164.2.1037. View

11.

Hong Y, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown L . VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004; 18(10):1111-3. DOI: 10.1096/fj.03-1179fje. View

12.

Heid C, Stevens J, Livak K, Williams P . Real time quantitative PCR. Genome Res. 1996; 6(10):986-94. DOI: 10.1101/gr.6.10.986. View

13.

Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29. DOI: 10.1038/nrc2780. View

14.

Li M, Wan Y, Sanjabi S, Robertson A, Flavell R . Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006; 24:99-146. DOI: 10.1146/annurev.immunol.24.021605.090737. View

15.

Hazlett L, McClellan S, Kwon B, Barrett R . Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive. Invest Ophthalmol Vis Sci. 2000; 41(3):805-10. View

16.

Wu M, McClellan S, Barrett R, Hazlett L . Beta-defensin-2 promotes resistance against infection with P. aeruginosa. J Immunol. 2009; 182(3):1609-16. DOI: 10.4049/jimmunol.182.3.1609. View

17.

Hu D, Hiley C, Fan T . Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model. Br J Pharmacol. 1996; 117(3):545-551. PMC: 1909324. DOI: 10.1111/j.1476-5381.1996.tb15225.x. View

18.

Delgado M, Pozo D, Ganea D . The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004; 56(2):249-90. DOI: 10.1124/pr.56.2.7. View

19.

Gressens P, Paindaveine B, Hill J, Brenneman D, Evrard P . Growth factor properties of VIP during early brain development. Whole embryo culture and in vivo studies. Ann N Y Acad Sci. 1997; 814:152-60. DOI: 10.1111/j.1749-6632.1997.tb46153.x. View

20.

Moon M, Hazlett L, Hancock R, Berk R, Barrett R . Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 1988; 29(8):1277-84. View